228 related articles for article (PubMed ID: 24885829)
1. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability.
Brändstedt J; Wangefjord S; Nodin B; Eberhard J; Jirström K; Manjer J
BMC Cancer; 2014 May; 14():371. PubMed ID: 24885829
[TBL] [Abstract][Full Text] [Related]
2. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.
Wangefjord S; Brändstedt J; Lindquist KE; Nodin B; Jirström K; Eberhard J
Diagn Pathol; 2013 Jan; 8():10. PubMed ID: 23337059
[TBL] [Abstract][Full Text] [Related]
3. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer.
Nodin B; Johannesson H; Wangefjord S; O'Connor DP; Lindquist KE; Uhlén M; Jirström K; Eberhard J
Diagn Pathol; 2012 Aug; 7():115. PubMed ID: 22935204
[TBL] [Abstract][Full Text] [Related]
4. Influence of anthropometric factors on tumour biological characteristics of colorectal cancer in men and women: a cohort study.
Brändstedt J; Wangefjord S; Borgquist S; Nodin B; Eberhard J; Manjer J; Jirström K
J Transl Med; 2013 Nov; 11():293. PubMed ID: 24256736
[TBL] [Abstract][Full Text] [Related]
5. Breast tumours following combined hormone replacement therapy express favourable prognostic factors.
Borgquist S; Anagnostaki L; Jirström K; Landberg G; Manjer J
Int J Cancer; 2007 May; 120(10):2202-7. PubMed ID: 17278089
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptives, hormone replacement therapy and breast cancer risk: a cohort study of 16 928 women 48 years and older.
Thorbjarnardottir T; Olafsdottir EJ; Valdimarsdottir UA; Olafsson O; Tryggvadottir L
Acta Oncol; 2014 Jun; 53(6):752-8. PubMed ID: 24460068
[TBL] [Abstract][Full Text] [Related]
7. Postmenopausal hormone replacement therapy and colorectal cancer risk by molecular subtypes and pathways.
Amitay EL; Carr PR; Jansen L; Alwers E; Roth W; Herpel E; Kloor M; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
Int J Cancer; 2020 Aug; 147(4):1018-1026. PubMed ID: 31943160
[TBL] [Abstract][Full Text] [Related]
8. HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
Bengtsson E; Nerjovaj P; Wangefjord S; Nodin B; Eberhard J; Uhlén M; Borgquist S; Jirström K
Diagn Pathol; 2014 Apr; 9():78. PubMed ID: 24708688
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the correlation of KAI1/CD82, CD44, MMP7 and β-catenin in the prediction of prognosis and metastasis in colorectal carcinoma.
Wu Q; Yang Y; Wu S; Li W; Zhang N; Dong X; Ou Y
Diagn Pathol; 2015 Sep; 10():176. PubMed ID: 26408312
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression.
Lin JH; Morikawa T; Chan AT; Kuchiba A; Shima K; Nosho K; Kirkner G; Zhang SM; Manson JE; Giovannucci E; Fuchs CS; Ogino S
Cancer Res; 2012 Jun; 72(12):3020-8. PubMed ID: 22511578
[TBL] [Abstract][Full Text] [Related]
11. Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women.
Limsui D; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Harnack LJ; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
Gut; 2012 Sep; 61(9):1299-305. PubMed ID: 22027477
[TBL] [Abstract][Full Text] [Related]
12. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of BMP and activin membrane-bound inhibitor in colorectal cancer.
Togo N; Ohwada S; Sakurai S; Toya H; Sakamoto I; Yamada T; Nakano T; Muroya K; Takeyoshi I; Nakajima T; Sekiya T; Yamazumi Y; Nakamura T; Akiyama T
World J Gastroenterol; 2008 Aug; 14(31):4880-8. PubMed ID: 18756595
[TBL] [Abstract][Full Text] [Related]
14. Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia.
Aissi S; Buisine MP; Zerimech F; Kourda N; Moussa A; Manai M; Porchet N
World J Gastroenterol; 2013 Aug; 19(32):5286-94. PubMed ID: 23983431
[TBL] [Abstract][Full Text] [Related]
15. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival.
Firestein R; Shima K; Nosho K; Irahara N; Baba Y; Bojarski E; Giovannucci EL; Hahn WC; Fuchs CS; Ogino S
Int J Cancer; 2010 Jun; 126(12):2863-73. PubMed ID: 19790197
[TBL] [Abstract][Full Text] [Related]
16. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
17. Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes.
Mehta RS; Song M; Nishihara R; Drew DA; Wu K; Qian ZR; Fung TT; Hamada T; Masugi Y; da Silva A; Shi Y; Li W; Gu M; Willett WC; Fuchs CS; Giovannucci EL; Ogino S; Chan AT
Gastroenterology; 2017 Jun; 152(8):1944-1953.e1. PubMed ID: 28249812
[TBL] [Abstract][Full Text] [Related]
18. p53, Cyclin-D1, β-catenin, APC and c-myc in Tumor Tissue from Colorectal and Gastric Cancer Patients with Suspected Lynch Syndrome by the Bethesda Criteria.
Marcolino TF; Pimenta CAM; Artigiani Neto R; Castelo P; Silva MS; Forones NM; Oshima CTF
Asian Pac J Cancer Prev; 2020 Feb; 21(2):343-348. PubMed ID: 32102509
[TBL] [Abstract][Full Text] [Related]
19. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
Thomas ML; Hewett PJ; Ruszkiewicz AR; Moore JW
Asia Pac J Clin Oncol; 2015 Dec; 11(4):343-51. PubMed ID: 26471980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
